Urological Device Market Will Grow to More Than
Prostate cancer is the leading non-dermal cancer among American males and is diagnosed in approximately 150 out of every 100,000 men. External beam radiation therapy is currently the most frequently used primary treatment method for prostate cancer, but it is predicted to be overtaken by robotic prostatectomy surgery by 2013. However, external radiation is still expected to be a popular secondary treatment, and will be used on over 40% of patients. Other treatments include brachytherapy, cryotherapy and high-intensity focused ultrasound (HIFU), with the developing market for HIFU estimated to grow at a compound annual growth rate (CAGR) of 91% by 2016.
"With growing patient awareness and an emphasis on early detection of prostate cancer and BPH, we are seeing more patients diagnosed," says Dr.
iData's Urological Devices series provides a comprehensive analysis of the prostate cancer treatment market including brachytherapy, cryotherapy, external beam radiation, HIFU and robotic prostatectomy systems. The reports cover the BPH treatment device market, including devices for TURP, TUMT, TUNA, prostatic stents and laser BPH treatment. In addition, they include incontinence treatment, bladder cancer fulguration, urodynamic equipment, stone treatment, urological endoscopes and nephrostomy devices.
View more information by registering free on iData's website at: http://www.idataresearch.net/idata/registration.php
About iData Research
iData Research (www.idataresearch.net/idata/discoveridata.php) is an international market research and consulting group focused on providing market intelligence for medical device, dental and pharmaceutical companies. iData covers research in: urology, gynecology, endoscopy, orthopedics, cardiovascular, dental, pharmaceuticals and more.
SOURCE iData Research Inc.